Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 7/20 | 0.33 |
| ▸ | GAA | P10253 | 7/20 | 0.33 |
| ▸ | SI | P14410 | 7/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 7/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7928100 | 0.79 | CCR1 (0.46) | ATMKMT2A | |
| SCHEMBL17175158 | 0.76 | HTR1D (0.49) | ATMGAALMNA | |
| SCHEMBL3222307 | 0.76 | ATM (0.36) | ATMMGAMGAASIMGAM2 | |
| SCHEMBL17066966 | 0.76 | MTNR1A (0.42) | LMNAMEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL18853863 | 0.76 | FFAR1 (0.33) | LMNA | |
| SCHEMBL3219741 | 0.73 | HTR1D (0.51) | ATMMEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL30577622 | 0.73 | PIM1 (0.42) | ATMMEN1KMT2A | |
| SCHEMBL14961107 | 0.73 | MTNR1A (0.43) | MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL29957479 | 0.72 | CYP2A6 (0.42) | MEN1KMT2A | |
| SCHEMBL17026983 | 0.72 | AHR (0.35) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789089-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-10 | — | — | US | disclosed |
| US-9220710-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | ATM 3099/4885MGAM 2206/4885GAA 18/4885 |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | ATM 3099/4885MGAM 2206/4885GAA 18/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | ATM 4697/4885MGAM 2864/4885GAA 148/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | ATM 4697/4885MGAM 2864/4885GAA 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.